BANK OF AMERICA CORP /DE/ - AMNEAL PHARMACEUTICALS INC ownership

AMNEAL PHARMACEUTICALS INC's ticker is AMRX and the CUSIP is 03168L105. A total of 135 filers reported holding AMNEAL PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.68 and the average weighting 0.1%.

Quarter-by-quarter ownership
BANK OF AMERICA CORP /DE/ ownership history of AMNEAL PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$1,091,335
+220.0%
258,610
+135.1%
0.00%
Q2 2023$341,065
+94.8%
110,021
-12.7%
0.00%
Q1 2023$175,123
-90.7%
125,987
-86.6%
0.00%
Q4 2022$1,877,737
+1231.7%
943,586
+1250.0%
0.00%
Q3 2022$141,000
-36.5%
69,896
-0.1%
0.00%
Q2 2022$222,000
+60.9%
69,979
+110.9%
0.00%
Q1 2022$138,000
-54.3%
33,183
-47.3%
0.00%
Q4 2021$302,000
+39.2%
62,962
+54.2%
0.00%
Q3 2021$217,000
+17.3%
40,828
+12.8%
0.00%
Q2 2021$185,000
-65.4%
36,193
-54.5%
0.00%
Q1 2021$535,000
+234.4%
79,485
+127.4%
0.00%
Q4 2020$160,000
-78.9%
34,954
-82.2%
0.00%
Q3 2020$759,000
-61.1%
195,856
-52.3%
0.00%
Q2 2020$1,953,000
+12.2%
410,239
-18.0%
0.00%
Q1 2020$1,741,000
-49.9%
500,286
-30.7%
0.00%
Q4 2019$3,478,000
+407.7%
721,720
+205.8%
0.00%
Q3 2019$685,000
-80.6%
236,028
-52.1%
0.00%
-100.0%
Q2 2019$3,534,000
-47.9%
492,820
+2.9%
0.00%0.0%
Q1 2019$6,788,000
+64.8%
479,057
+57.4%
0.00%0.0%
Q4 2018$4,118,000
-31.6%
304,324
+12.2%
0.00%0.0%
Q3 2018$6,018,000
+64.9%
271,188
+22.0%
0.00%0.0%
Q2 2018$3,649,000222,3340.00%
Other shareholders
AMNEAL PHARMACEUTICALS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Fosun International Ltd 21,521,301$90,819,89014.58%
Eversept Partners, LP 2,644,988$11,161,8490.94%
TPG GP A, LLC 12,328,767$52,027,3970.90%
Nantahala Capital Management 2,212,757$9,337,8350.80%
Rubric Capital Management LP 4,024,500$16,983,3900.64%
Hedges Asset Management LLC 84,600$357,0120.31%
Signature Wealth Management Partners, LLC 66,666$281,3310.28%
Tejara Capital Ltd 96,672$407,9560.23%
Tranquilli Financial Advisor LLC 71,414$301,3670.22%
EAM Investors, LLC 230,271$971,7440.19%
View complete list of AMNEAL PHARMACEUTICALS INC shareholders